| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/27/2003 | WO2002017919A3 Use of threo-methylphenidate compounds to enhance memory |
| 02/27/2003 | WO2002016548A8 Novel g protein-coupled receptor |
| 02/27/2003 | WO2002008267A3 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 02/27/2003 | WO2002004605A3 Stimulation of cellular regeneration and differentiation in the inner ear |
| 02/27/2003 | WO2002002797A3 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 02/27/2003 | WO2002001950A3 Transgenic mice containing targeted gene disruptions |
| 02/27/2003 | WO2001098471A3 Human phosphodiesterases |
| 02/27/2003 | WO2001097860A3 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 02/27/2003 | WO2001092892A3 Methods to identify compounds that modulate rage |
| 02/27/2003 | WO2001075164A3 Rna sequence-specific mediators of rna interference |
| 02/27/2003 | US20030041341 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding 4E-BP1 |
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040535 Tetrazole compounds as thyroid receptor ligands |
| 02/27/2003 | US20030040533 For use as hypoglycaemic and hypolipidaemic agents |
| 02/27/2003 | US20030040529 Combined agents for treatment of glaucoma |
| 02/27/2003 | US20030040524 Pyrimidine compounds and methods for making and using the same |
| 02/27/2003 | US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 02/27/2003 | US20030040510 Selective estrogen receptor modulators in combination with estrogens |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040507 Pharmaceutical composition comprising ifosfamide and carnitine |
| 02/27/2003 | US20030040490 Drugs containing combined active ingredients |
| 02/27/2003 | US20030040486 Alternating intrathecal administration to the mammal of a pharmaceutically effective dose of opioid receptor agonist for first period of time, and dose of at least one opioid receptor-like receptor 1 agonist for a second period of time |
| 02/27/2003 | US20030040464 Method of treating or preventing attention defecit hyperactivity disorder |
| 02/27/2003 | US20030040461 Providing a cell expressing Bruton's Tyrosine Kinase; contacting cell expressing Bruton's Tyrosine Kinase with a test compound; determining whether test compound modulates the activity of Bruton's Tyrosine Kinase |
| 02/27/2003 | US20030040112 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 02/27/2003 | US20030040111 Differentiated cells suitable for human therapy |
| 02/27/2003 | US20030040044 Anti-dual integrin antibodies, compositions, methods and uses |
| 02/27/2003 | US20030039707 ATP synthesis activator |
| 02/27/2003 | US20030039705 Triterpene compositions and methods for use thereof |
| 02/27/2003 | US20030039689 Prodrug in polymer matrix; insertion into body |
| 02/27/2003 | US20030039686 Increased absorption; aqueous solution containing fatty acid, or salt thereof |
| 02/27/2003 | US20030039666 Use of parasitic biological agents for prevention and control of autoimmune diseases |
| 02/27/2003 | US20030039656 Modified reoviral therapy |
| 02/27/2003 | US20030039647 Tetraspan protein and uses thereof |
| 02/27/2003 | US20030039641 Cells expressing anti-fc receptor binding components |
| 02/27/2003 | US20030039640 Infecting cells with a retrovirus in the presence of an immobilized material including a ligand which bings to the cell and a ligand which binds to the retrovirus |
| 02/27/2003 | US20030039639 Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| 02/27/2003 | US20030039638 Administering to a donor a pharmaceutical composition containing carbon monoxide, obtaining an organ, tissue or cell and transplanting to a recipient |
| 02/27/2003 | US20030039629 Espression enhancer for protein synthesis inhibitory genes |
| 02/27/2003 | US20030039614 Expanding the homogeneous solution by exposing it to a change in pressure under conditions such that the solution or homogeneous dispersion does not boil |
| 02/27/2003 | US20030039611 Selectively binds to antigen to cause cell impairment |
| 02/27/2003 | CA2459692A1 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | CA2459434A1 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders |
| 02/27/2003 | CA2458648A1 Secreted proteins |
| 02/27/2003 | CA2458643A1 Nucleic-acid associated proteins |
| 02/27/2003 | CA2458625A1 Transporters and ion channels |
| 02/27/2003 | CA2458068A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | CA2457932A1 Sodium channel regulators and modulators |
| 02/27/2003 | CA2457789A1 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 02/27/2003 | CA2457783A1 Oligonucleotide compositions and their use to induce apoptosis |
| 02/27/2003 | CA2457745A1 Combination therapy for the treatment of cancer |
| 02/27/2003 | CA2457644A1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect |
| 02/27/2003 | CA2457632A1 Identification and isolation of somatic stem cells and uses thereof |
| 02/27/2003 | CA2457611A1 Novel molecular target for neurotoxicity |
| 02/27/2003 | CA2457595A1 A method of producing antibodies ex-vivo |
| 02/27/2003 | CA2457482A1 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 02/27/2003 | CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | CA2457436A1 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 02/27/2003 | CA2457143A1 In situ immunization |
| 02/27/2003 | CA2457142A1 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 02/27/2003 | CA2457043A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 02/27/2003 | CA2457041A1 Novel combination |
| 02/27/2003 | CA2457033A1 A medecine for cardiac failure |
| 02/27/2003 | CA2456985A1 2h-phthalazin-1-ones and methods for use thereof |
| 02/27/2003 | CA2456966A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | CA2456868A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | CA2456743A1 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | CA2456206A1 Sodium salt of an hiv integrase inhibitor |
| 02/27/2003 | CA2456150A1 Selective estrogen receptor modulators |
| 02/27/2003 | CA2455974A1 Methods for purification of an activated peg solution and for the synthesis of a modified hemoglobin solution |
| 02/27/2003 | CA2455827A1 Materials and methods for nerve grafting comprising degrading chondroitin sulfate proteoglycan |
| 02/27/2003 | CA2454860A1 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 02/27/2003 | CA2454762A1 Isoxazolopyridinones |
| 02/27/2003 | CA2454756A1 Methods and compounds for the targeting of protein to exosomes |
| 02/27/2003 | CA2454083A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | CA2453962A1 Diazacycloalkanes as oxytocin agonists |
| 02/27/2003 | CA2453647A1 1-alkyl 0r 1-cycloalkyltriazolo¬4,3-a|quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/27/2003 | CA2452801A1 Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders |
| 02/27/2003 | CA2451998A1 Anti-a.beta. antibodies |
| 02/27/2003 | CA2423025A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 02/26/2003 | WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient |
| 02/26/2003 | EP1286165A2 Neuropeptide receptor and uses thereof |
| 02/26/2003 | EP1285964A2 Human Mater proteins |
| 02/26/2003 | EP1285927A2 Use of glucocorticoid antagonists for the prevention and treatment of diseases of the male reproductive system |
| 02/26/2003 | EP1285922A1 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | EP1285916A1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels |
| 02/26/2003 | EP1285908A1 Substituted phenylpropionic acid derivatives |
| 02/26/2003 | EP1285885A1 High functional water containing titanium and method and apparatus for producing the same |
| 02/26/2003 | EP1285658A2 Treatments for female sexual dysfunction |
| 02/26/2003 | EP1285656A1 Acetylcholinesterase inhibitors containing 1-benzyl- pyridinium salts |
| 02/26/2003 | EP1285653A1 Use of alpha-1L agonists in the treatment of incontinence |
| 02/26/2003 | EP1285652A1 Novel fatty acid analogues for the treatment of hypertension |
| 02/26/2003 | EP1285650A1 Method and compositions for inhibiting arteriosclerosis |
| 02/26/2003 | EP1285087A2 Enzymatic assays for screening anti-cancer agents |
| 02/26/2003 | EP1285063A1 Anti-angiogenic polypeptides |
| 02/26/2003 | EP1285061A1 Antisense modulation of pten expression |
| 02/26/2003 | EP1285001A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof |
| 02/26/2003 | EP1285000A2 Use of adnf for enhancing learning and memory |
| 02/26/2003 | EP1284996A2 Therapeutic anti-melanoma compounds |